Compare Sana Biotechnology Inc (SANA) vs Stellantis N.V. Common Shares (STLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Stellantis N.V. Common Shares — how do they compare? Sana Biotechnology Inc trades at $2.33 (market cap $697.51M), while Stellantis N.V. Common Shares trades at $4.27 (market cap $16.20B). The key difference: Stellantis N.V. Common Shares is far larger — about 23.2× Sana Biotechnology Inc's market cap, and Stellantis N.V. Common Shares is more actively traded (30,607,418 versus 2,763,583). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 24 Days and Stellantis N.V. Common Shares for 0 Days on average.
| SANA | STLA | |
|---|---|---|
Market Cap | $697.51M | $16.20B |
Volume | 2,763,583 | 30,607,418 |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $12.12 |
52-Week Low | $2.33 | $4.27 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $610.76M | $35.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sana Biotechnology (SANA) trades at $2.41, down 8.02% in the last session, reflecting a bearish technical trend despite bullish oscillators. The company is pre-revenue with significant losses, reporting a net income of -$244.17 million in 2025 and negative cash flow, while maintaining a price-to-book ratio of 4.51. Recent news highlights active participation in investor conferences and a positive analyst consensus.
The outlook is speculative, with high risk due to no current revenue and substantial cash burn, but potential upside exists if clinical developments succeed, supported by an analyst consensus price target of $8.50. Key risks include funding needs, clinical trial outcomes, and competitive pressures in biotechnology.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Stellantis N.V. Common Shares
Stellantis N.V. is a multinational automaker formed from the 2021 merger of Fiat Chrysler Automobiles and PSA Group, manufacturing vehicles under brands including Jeep, Ram, Chrysler, Dodge, Fiat, Peugeot, and Citroën.
Read more on STLA →
